Search

This study was conducted to evaluate the safety profile of Pantohematogen, a substance derived from the velvet antlers of the Altai Wapiti, which is commonly used as a functional ingredient in dietary supplements. In this clinical research, both male and female Wistar rats received the maximum tolerable intragastric dose of Pantohematogen. Over the course of six months, researchers monitored the animals for changes in general health status, body mass, hematologic and bone marrow parameters, and the functioning of major organs, including the liver, kidneys, heart, and brain.Throughout the experimental period, the animals exhibited stable behavior and maintained normal fur condition, appetite, reflex responses, and gastrointestinal and urinary tract function. No signs of a toxic response were detected following intragastric administration. However, administration of Pantohematogen at 250 and 500 mg/kg resulted in increased liver mass and reduced testicular size in male rats. This condition persisted for 2 weeks after treatment cessation. Other internal organs showed no abnormalities when compared with control and untreated animals.Importantly, the tested doses exceeded standard human-equivalent levels (per kilogram of body weight) by factors of 2, 10, and 20, respectively. Despite this, the findings indicated no evident toxicological impact from Pantohematogen exposure. This research was conducted at the Tomsk National Research Medical Center of the Russian Academy of Sciences under the supervision of Dr. N.I. Suslov, Doctor of Medical Science.

Programmable drug delivery systems are emerging as a transformative class of therapeutic technologies because they can adjust drug release according to physiological signals, algorithmic rules, or external commands. Their appeal lies in the promise of more responsive, individualised, and continuous therapy than is possible with conventional dosage forms. Closed-loop insulin delivery, implantable programmable pumps, responsive antidote systems, and digitally mediated delivery platforms all illustrate this shift from passive administration to active therapeutic control. This shift also changes the ethical character of drug delivery. When a device senses, interprets, and acts on behalf of a patient, dosing becomes partly delegated to software, control architecture, and design assumptions. The ethical question is therefore not only whether the system works, but whether it preserves the patient’s agency while pursuing therapeutic optimisation. The core problem is that programmable delivery systems combine pharmacological intervention, medical device operation, data processing, and algorithmic decision-making in a single therapeutic object. This convergence creates tensions between efficiency and autonomy, adaptability and safety assurance, and automation and human oversight. Existing ethical and regulatory vocabularies do not fully capture these tensions because they often treat drugs, devices, software, and clinical decisions as separable domains. This critical perspective argues that programmable drug delivery requires an ethical design approach from the earliest stages of development. Autonomy must be translated into design features such as consent clarity, override capacity, patient-facing explanation, and withdrawal options. Safety must be treated as a lifecycle property rather than a static pre-market claim. The article proposes a critical framework for classifying programmable delivery systems according to autonomy level, identifying ethical pressure points, and linking them to design and governance requirements. It argues that trustworthy programmable delivery depends not merely on technical performance, but on the deliberate preservation of meaningful human control. Ethical foresight must therefore become part of the engineering logic of programmable drug delivery itself.